ReviewMarine drugs2018
Overview on the Antihypertensive and Anti-Obesity Effects of Secondary Metabolites from Seaweeds.
Review in Marine drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 116 citations in OpenAlex.
- Effect of Dietary Nori (Dried Laver) on Blood Pressure in Young Japanese Children: An Intervention Study.Journal of epidemiology · 2021Trial
- Navigating the potential of algal peptides: health effects, market applications, and scientific challenges.Annals of medicine · 2026Review
- Phytochemicals with potential NMDAR-inhibitory activities: a review of neuroprotective mechanisms against excitotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Algae-Derived Bioactive Compounds as Platforms for Translational Biotechnology and Health Applications.Biotech (Basel (Switzerland)) · 2026Review
- Secret heroes of the sea: brown macroalgae and their bioactive powers-a narrative review.Frontiers in nutrition · 2026Review
- Phlorotannins and glycolipid metabolism: comprehensive regulatory roles mediated by the gut microbiota.Frontiers in nutrition · 2026Review
- Combined Potential of Orlistat with Natural Sources and Their Bioactive Compounds Against Obesity: A Review.Molecules (Basel, Switzerland) · 2025Review
- Revolutionizing Diabetes Care: The Role of Marine Bioactive Compounds and Microorganisms.Cell biochemistry and biophysics · 2025Review
- Fucoxanthin Inhibits the NMDA and AMPA Receptors Through Regulating the Calcium Response on Substantia Gelatinosa Neurons of the Trigeminal Subnucleus Caudalis in Juvenile Mice.Neural plasticity · 2025Article
- Novel Therapeutic Approach for Obesity: Seaweeds as an Alternative Medicine with the Latest Conventional Therapy.Medical sciences (Basel, Switzerland) · 2024Review
- pH-Dependent Extraction of Antioxidant Peptides from Red SeaweedMarine drugs · 2024Article
- Insights into the physiology, biochemistry and ecological significance of the red seaweed Tricleocarpa fragilis in the Andaman Sea.BMC plant biology · 2024Article
- Effect of Macro and Microalgae Addition on Nutritional, Physicochemical, Sensorial, and Functional Properties of a Vegetable Cream.Foods (Basel, Switzerland) · 2024Article
- Advances in oligosaccharides production from brown seaweeds: extraction, characterization, antimetabolic syndrome, and other potential applications.Bioengineered · 2023Review
- Bioactive molecules from terrestrial and seafood resources in hypertension treatment: focus on molecular mechanisms and targeted therapies.Natural products and bioprospecting · 2023Review
- Review
- Effect of Deployment and Harvest Date on Growth and High-Value Compounds of FarmedMarine drugs · 2023Article
- A comprehensive review on algal nutraceuticals as prospective therapeutic agent for different diseases.3 Biotech · 2023Review
- Identification of Bioactive Peptides from aMarine drugs · 2023Article
- Recent advances in the extraction, purification, structural-property correlations, and antiobesity mechanism of traditional Chinese medicine-derived polysaccharides: a review.Frontiers in nutrition · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension and obesity are two significant factors that contribute to the onset and exacerbation of a cascade of mechanisms including activation of the sympathetic and renin-angiotensin systems, oxidative stress, release of inflammatory mediators, increase of adipogenesis and thus promotion of systemic dysfunction that leads to clinical manifestations of cardiovascular diseases. Seaweeds, in addition to their use as food, are now unanimously acknowledged as an invaluable source of new natural products that may hold noteworthy leads for future drug discovery and development, including in the prevention and/or treatment of the cardiovascular risk factors. Several compounds including peptides, phlorotannins, polysaccharides, carotenoids, and sterols, isolated from brown, red and green macroalgae exhibit significant anti-hypertensive and anti-obesity properties. This review will provide a comprehensive overview of the recent advances on bioactive pure compounds isolated from different seaweed sources focusing on their potential use as drugs to treat or prevent hypertension and obesity. On the other hand, although it is obvious that macroalgae represent promising sources of antihypertensive and anti-obesity compounds, it is also clear that further efforts are required to fully understand their cellular mechanisms of action, to establish structure-inhibition relationships and mainly to evaluate them in pre-clinical and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.